Golden Throat Holdings Group Company Limited (6896.HK)

HKD 4.25

(-0.47%)

Net Income Summary of Golden Throat Holdings Group Company Limited

  • Golden Throat Holdings Group Company Limited's latest annual net income in 2023 was 250.16 Million CNY , down -11.04% from previous year.
  • Golden Throat Holdings Group Company Limited's latest quarterly net income in 2023 FY was 250.16 Million CNY , down -11.04% from previous quarter.
  • Golden Throat Holdings Group Company Limited reported an annual net income of 281.21 Million CNY in 2022, up 49.87% from previous year.
  • Golden Throat Holdings Group Company Limited reported an annual net income of 187.64 Million CNY in 2021, up 21.8% from previous year.
  • Golden Throat Holdings Group Company Limited reported a quarterly net income of 250.16 Million CNY for 2023 FY, down -11.04% from previous quarter.
  • Golden Throat Holdings Group Company Limited reported a quarterly net income of 122.14 Million CNY for 2023 Q2, down -45.59% from previous quarter.

Annual Net Income Chart of Golden Throat Holdings Group Company Limited (2023 - 2013)

Historical Annual Net Income of Golden Throat Holdings Group Company Limited (2023 - 2013)

Year Net Income Net Income Growth
2023 250.16 Million CNY -11.04%
2022 281.21 Million CNY 49.87%
2021 187.64 Million CNY 21.8%
2020 154.05 Million CNY -8.09%
2019 167.61 Million CNY 64.03%
2018 102.18 Million CNY 66.48%
2017 61.38 Million CNY -40.36%
2016 102.91 Million CNY -33.44%
2015 154.61 Million CNY 26.85%
2014 121.89 Million CNY 74.34%
2013 69.91 Million CNY 0.0%

Peer Net Income Comparison of Golden Throat Holdings Group Company Limited

Name Net Income Net Income Difference
Pak Fah Yeow International Limited 105.03 Million HKD -138.161%
Grand Pharmaceutical Group Limited 1.87 Billion HKD 86.693%
Extrawell Pharmaceutical Holdings Limited -162.94 Million HKD 253.522%
Wai Yuen Tong Medicine Holdings Limited -15.35 Million HKD 1729.083%
Qianhai Health Holdings Limited -52.7 Million HKD 574.646%
Lee's Pharmaceutical Holdings Limited 16.69 Million HKD -1398.155%
Essex Bio-Technology Limited 275.25 Million HKD 9.118%
Tongfang Kontafarma Holdings Limited -28.84 Million HKD 967.323%
PuraPharm Corporation Limited -106.08 Million HKD 335.822%
SSY Group Limited 1.31 Billion HKD 81.028%
JBM (Healthcare) Limited 130.46 Million HKD -91.749%
Jacobson Pharma Corporation Limited 266.96 Million HKD 6.295%
China Resources Pharmaceutical Group Limited 3.85 Billion HKD 93.509%